-
Tipo NewsBANDO
-
FonteVarie - UE
-
Del
La Innovative Medicines Initiative (IMI 2), la più grande iniziativa europea di natura pubblico-privata creata per accelerare lo sviluppo di farmaci migliori e più sicuri per i pazienti, ha pubblicato ufficialmente due nuovi bandi (15° e 16°).
Inoltre, IMI ha annunciato l'Antimicrobial resistance (AMR) accelerator programme, un programma dedicato alla resistenza antimicrobica che si concentrerà su tre ambiti principali:
- Pillar A: Capability building network (CBN)
- Pillar B: Tuberculosis drug development network (TBDDN)
- Pillar C: Company-specific portfolio building networks (PBNs)
Di seguito i topic inclusi nei due bandi:
Identificativo bando: H2020-JTI-IMI2-2018-15-TWO-STAGE
- IMI2-2018-15-01: Integrated research platforms enabling patient-centric drug development
- IMI2-2018-15-02: Blockchain Enabled Healthcare
- IMI2-2018-15-03: Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases
- IMI2-2018-15-04: Emerging translational safety technologies and tools for interrogating human immuno-biology
- IMI2-2018-15-05: Development and validation of translational platforms in support of synaptopathy drug discovery
- IMI2-2018-15-06: Digital endpoints in neurodegenerative and immune-mediated diseases
- IMI2-2018-15-07: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
- IMI2-2018-15-08: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
Il bando seguirà una valutazione a due fasi; il termine ultime per presentare la propria proposta First stage è fissata al 24 ottobre 2018, mentre le proposte selezionare dovranno presentare la proposta progettuale completa entro il 15 maggio 2019.
Identificativo bando: H2020-JTI-IMI2-2018-16-SINGLE-STAGE
- IMI2-2018-16-01: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
- IMI2-2018-16-02: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
- IMI2-2018-16-03: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
- IMI2-2018-16-04: Determination of gepotidacin levels in tonsils and prostatic tissue
- IMI2-2018-16-05: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
- IMI2-2018-16-06: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
- IMI2-2018-16-07: Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
Il termine ultime per presentare la propria proposta è fissata al 24 ottobre 2018.
433.669.762
